1
|
Squillace N, Ricci E, Colella E, Bonfanti P. HIV and SARS-CoV-2 Co-Infection: What are the Risks? Infect Drug Resist 2021; 14:3991-4014. [PMID: 34611416 PMCID: PMC8487262 DOI: 10.2147/idr.s277899] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 09/08/2021] [Indexed: 12/14/2022] Open
Abstract
The dramatic increase of the global pandemic of SARS-CoV-2 infection represents a critical issue that needs to be investigated to evaluate the associated risk factors for acquisition and worse outcome. The interplay between immune activation and immune depression during SARS-CoV-2 infection is an intriguing topic that still needs to be clarified. The role of HIV in SARS-CoV-2 infection is not well defined. Chronic inflammation linked to HIV infection could be a driver for a worse prognosis in people living with HIV (PLWH). We explored the role of HIV as a risk factor for SARS-CoV-2 infection and severity and which factors contributed to a worse prognosis when HIV infection was present. PubMed/MEDLINE was searched for "COVID-19" or "SARS-CoV2" and "HIV" or "AIDS" and ("hospitalization" or "intensive care" or "mechanical ventilation" or "death" OR "mortality"), both in MeSH and as free text in all fields. Our review focused on 21 studies that enrolled at least 40 PLWH. In most studies, HIV infection did not represent a risk factor for SARS-CoV-2 infection. On the contrary, the risk of severe COVID-19 and hospitalization was higher in PLWH. Low CD4 cell count consistently emerged as a risk factor for severe COVID-19. Comorbidities, either in people with or without HIV diagnosis, played a key role, especially because of their early development in PLWH.
Collapse
Affiliation(s)
- Nicola Squillace
- Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy
| | | | - Elisa Colella
- Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy
| | - Paolo Bonfanti
- Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy
| |
Collapse
|
2
|
Squillace N, Bernasconi DP, Lapadula G, Soria A, Sabbatini F, Colella E, Rossi M, Tamburini AM, Leone BE, Brenna A, Malandrin S, Cavallero A, Di Lucia A, Braga M, Bonfanti P. HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation. HIV Med 2021; 22:860-866. [PMID: 34293254 DOI: 10.1111/hiv.13143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 06/24/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVES The aim of the present study was too investigate prevalence and persistence of human papilloma virus (HPV) and cytological abnormalities (CAs) in the anal swabs of people living with HIV (PLWH): men who have sex with men (MSM), men who have sex with women (MSW) and women (W). METHODS Between March 2010 and January 2019, an anal swab for cytological and HPV genotyping tests was offered to all PLWH attending our clinic. Logistic regression analysis was conducted to identify predictors of infection. RESULTS In all, 354 PLWH were screened: 174 MSM, 90 MSW and 61 W. Prevalence of at least one high-risk (HR) HPV was higher in MSM (91%) and W (85%) than in MSW (77%) (P < 0.05). Cytological abnormalities were found in 21.1% of the entire population. At multivariable regression analysis a lower risk for HPV infection was found for W than for MSM [odds ratio = 0.24 (95% confidence interval: 0.115-0.513)] and for MSW than for MSM [0.37 (0.180-0.773)] and there was a significantly higher risk of CAs in PLWH with HPV 16 and 18 [3.3 (1.04-10.49)]. A total of 175 PLWH (103 MSM, 33 MSW and 26 W) had at least one follow-up visit (T1) after a median (interquartile range) follow-up of 3.6 (2.1-5.7) years. The acquisition rate of HR-HPV was high, with 66.7% of PLWH negative for HR-HPV at T0 who became positive at T1 (P < 0.001). The prevalence of CAs was stable (20.6%). A significant association between CAs at T1 and persistence of HPV-16 and/or 18 was found (P < 0.05). CONCLUSIONS HPV 16 and 18 are associated with the presence and development of CAs irrespective of sexual orientation.
Collapse
Affiliation(s)
- Nicola Squillace
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Davide Paolo Bernasconi
- Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
| | - Giuseppe Lapadula
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Alessandro Soria
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Francesca Sabbatini
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Elisa Colella
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Marianna Rossi
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | | | - Biagio Eugenio Leone
- Pathology, Department of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - Ambrogio Brenna
- Pathology, Department of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - Sergio Malandrin
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Annalisa Cavallero
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Adriana Di Lucia
- Department of Surgery, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Marco Braga
- Department of Surgery, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| | - Paolo Bonfanti
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy
| |
Collapse
|
3
|
Fabbiani M, Borghetti A, Squillace N, Colafigli M, Taramasso L, Lombardi A, Rossetti B, Ciccullo A, Colella E, Picarelli C, Berruti M, Latini A, Montagnani F, Sambo M, Di Biagio A, Gori A, Di Giambenedetto S, Bandera A. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. J Acquir Immune Defic Syndr 2021; 86:119-127. [PMID: 33306566 DOI: 10.1097/qai.0000000000002525] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND We explored predictors of CD4/CD8 ratio improvement and optimal immunological recovery (OIR) after initiation of antiretroviral therapy (ART) in naive people living with HIV (PLWH). METHODS Retrospective multicenter study including naive PLWH starting ART with 2 nucleos(t)ide reverse transcriptase inhibitors + 1 integrase strand transfer inhibitor (InSTI) or non-NRTI or protease inhibitor (PI). PLWH were followed from the time of ART initiation (baseline) to the discontinuation of first-line regimen, virological failure, death, or loss to follow-up. Estimated incidence and predictors of time to CD4/CD8 ratio normalization (defined as ≥1) and OIR (defined as CD4/CD8 ratio ≥ 1 plus CD4 ≥ 500 cells/µL plus CD4% ≥ 30%) were explored by Kaplan-Meier curves and Cox regression analysis. RESULTS Overall, 1428 PLWH (77.8% males, median age 39 years, 55.1% with positive cytomegalovirus (CMV) antibodies, median HIV-RNA 4.80 log copies/mL, median CD4 323 cells/µL, median CD4/CD8 ratio 0.32) were included, of which 21.5% (n = 307), 44.5% (n = 636), and 34% (n = 485) treated with InSTI-, PI-, and NNRTI-based regimens, respectively. The estimated proportion of CD4/CD8 normalization and OIR at 36 months was 38.6% and 32.9%, respectively. Multivariate analysis showed that InSTI-based regimens had a higher probability of CD4/CD8 ratio normalization and OIR both in the total population (P < 0.001 versus PI) and in advanced naive PLWH (P ≤ 0.001 versus PI and NNRTI). Moreover, subjects with positive CMV serology showed a lower probability of CD4/CD8 ratio normalization and OIR (P < 0.001). CONCLUSIONS InSTI-based regimens showed a better immune recovery, suggesting that the type of first-line ART can influence immune reconstitution. PLWH with positive CMV serology showed an increased risk of suboptimal immune recovery.
Collapse
Affiliation(s)
- Massimiliano Fabbiani
- Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
| | - Alberto Borghetti
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy
| | - Nicola Squillace
- Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy
| | - Manuela Colafigli
- Infectious Dermatology and Allergology, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - Lucia Taramasso
- Department of Health Sciences (DISSAL), Infectious Diseases Clinic, Policlinico San Martino Hospital, University of Genoa, Genova, Italy
| | - Andrea Lombardi
- Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milano, Italy
| | - Barbara Rossetti
- Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
| | - Arturo Ciccullo
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy
| | - Elisa Colella
- Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy
| | - Chiara Picarelli
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy
| | - Marco Berruti
- Department of Health Sciences (DISSAL), Infectious Diseases Clinic, Policlinico San Martino Hospital, University of Genoa, Genova, Italy
| | - Alessandra Latini
- Infectious Dermatology and Allergology, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - Francesca Montagnani
- Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
- Department of Medical Biotechnologies, University of Siena, Siena, Italy
| | - Margherita Sambo
- Infectious and Tropical Diseases Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - Antonio Di Biagio
- Department of Health Sciences (DISSAL), Infectious Diseases Clinic, Policlinico San Martino Hospital, University of Genoa, Genova, Italy
| | - Andrea Gori
- Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milano, Italy
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; and
| | - Simona Di Giambenedetto
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy
- Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy
| | - Alessandra Bandera
- Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milano, Italy
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; and
| |
Collapse
|
4
|
Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. Liver Int 2020; 40:769-777. [PMID: 31970845 DOI: 10.1111/liv.14386] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 01/10/2020] [Accepted: 01/15/2020] [Indexed: 01/24/2023]
Abstract
BACKGROUND & AIMS In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. METHODS Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. RESULTS Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P = .065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P = .007) and lower median pretreatment Log10 HCV-RNA (5.87 vs 6.20, P = .001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. CONCLUSIONS In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <<difficult-to-treat>> genotype.
Collapse
Affiliation(s)
- Alessandro Soria
- Division of Infectious Diseases, San Gerardo Hospital - ASST Monza, Monza, Italy
| | - Marco Fava
- Division of Infectious Diseases, San Gerardo Hospital - ASST Monza, Monza, Italy.,Medical School, University of Milano-Bicocca, Milan, Italy
| | - Davide P Bernasconi
- Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| | - Giuseppe Lapadula
- Division of Infectious Diseases, San Gerardo Hospital - ASST Monza, Monza, Italy
| | - Elisa Colella
- Division of Infectious Diseases, San Gerardo Hospital - ASST Monza, Monza, Italy
| | - Maria G Valsecchi
- Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| | | | - Roberta D'Ambrosio
- Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy
| | - Simona Landonio
- Infectious Diseases, Ospedale Luigi Sacco - ASST Fatebenefratelli Sacco, Milano, Italy
| | - Monica Schiavini
- Infectious Diseases, Ospedale Luigi Sacco - ASST Fatebenefratelli Sacco, Milano, Italy
| | - Angiola Spinetti
- Infectious Diseases, Spedali Civili - ASST Brescia, Brescia, Italy
| | - Canio Carriero
- Infectious Diseases, Spedali Civili - ASST Brescia, Brescia, Italy
| | - Elisabetta Degasperi
- Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy
| | | | | | - Paolo Viganò
- Ospedale di Legnano - ASST Ovest Milano, Legnano, Italy
| | - Hamid Hasson
- Infectious Diseases, San Raffaele Scientific Institute IRCCS, Milano, Italy
| | | | - Luisa Pasulo
- ASST Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy
| | - Chiara Baiguera
- Hepatitis Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Roberto Rossotti
- Hepatitis Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Maria Vinci
- Hepatitis Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Massimo Puoti
- Hepatitis Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | | | - Barbara Menzaghi
- Division of Infectious Diseases, Ospedale di Busto Arsizio - ASST Valle Olona, Busto Arsizio, Italy
| | - Andrea Lombardi
- Infectious Diseases, Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Italy
| | - Angelo Pan
- Division of Infectious Diseases, ASST Cremona, Cremona, Italy
| | - Alessio Aghemo
- Internal Medicine and Hepatology, Humanitas Research Hospital IRCCS and Humanitas University, Rozzano, Italy
| | - Paolo A Grossi
- Ospedale di Circolo e Fondazione Macchi Varese - ASST Sette Laghi, Infectious Diseases, Università dell'Insubria, Varese, Italy
| | | | | | - Mauro Viganò
- Ospedale San Giuseppe, University of Milan, Milano, Italy
| | - Maria G Rumi
- Ospedale San Giuseppe, University of Milan, Milano, Italy
| | | | - Luca Valenti
- Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy
| | | | - Anna De Bona
- Ospedale San Paolo - ASST Santi Paolo e Carlo, Milano, Italy
| | | | | | | | - Marie G Pigozzi
- Infectious Diseases, Spedali Civili - ASST Brescia, Brescia, Italy
| | - Chiara Molteni
- Division of Infectious Diseases, ASST Lecco, Lecco, Italy
| | - Paolo Bonfanti
- Division of Infectious Diseases, ASST Lecco, Lecco, Italy
| | | | - Paolo Perini
- Policlinico San Pietro, Bergamo HCV Network, Ponte San Pietro, Italy
| | - Andrea Capretti
- San Carlo Hospital - ASST Santi Paolo e Carlo, Milano, Italy
| | | | | | | | | | - Layla Pagnucco
- Infectious Diseases, Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Italy
| | - Sherrie Bhoori
- Gastro-Hepato-Pancreatic Surgery and Liver Transplant Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Riccardo Centenaro
- Ospedale di Vizzolo Predabissi - ASST Melegnano e Martesana, Vizzolo Predabissi, Italy
| | - Massimo Graffeo
- UO Gastroenterologia ed Endoscopia Digestiva, Epatologia, Fondazione Ospedaliera Poliambulanza, Rete HCV Brescia, Brescia, Italy
| | - Antonio Ciaccio
- Division of Gastroenterology, San Gerardo Hospital - ASST Monza, Monza, Italy
| | - Elena Dionigi
- Ospedale di Cernusco sul Naviglio - ASST Melegnano e Martesana, Cernusco sul Naviglio, Italy
| | | | | | | | - Giuliano Rizzardini
- Infectious Diseases, Ospedale Luigi Sacco - ASST Fatebenefratelli Sacco, Milano, Italy
| | | | - Pietro Lampertico
- Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy
| | | |
Collapse
|
5
|
Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation. HIV Res Clin Pract 2020; 21:34-43. [PMID: 32129161 DOI: 10.1080/25787489.2020.1734752] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity. With this aim we designed the DUAL study: a randomized, open-label, multicenter, 96 weeks-long pilot exploratory study in virologically suppressed HIV-1+ patients with the aim of evaluating the immunovirological success and the impact on non-HIV related morbidity of switching to a dual therapy with darunavir-ritonavir (DRV/r) and rilpivirine (RPV). We recruited patients who received a PI/r-containing HAART for ≥6 months, HIV-RNA < 50 cp/mL for ≥3 months, eGFR > 60 mL/min/1,73m2, without DRV or RPV RAMs. We randomized patients in arm A: RPV + DRV/r QD or arm B: ongoing triple therapy. The primary endpoint has been defined as the percentage of patients with HIV-RNA < 50 cp/mL at week 48 (ITT). VACS index, Framingham CVD risk (FRS) and urinary RBP (uRBP) were calculated. We used Chi-square or Fisher statistics for categorical variables and Mann-Whitney U for continuous ones. Forty-one patients were enrolled (22 in arm A, 14 in arm B, plus 5 screening failures): 30 patients reached 96 weeks: 100% had HIV-RNA < 50 cp/mL in arm A versus 91.7% in arm B. Similar changes were observed in median CD4/mL between baseline and week 96 (+59 versus - 31, p: n.s.). Thirty-one in arm A and 23 in arm B adverse events took place, whereas only 1 was serious (arm A: turbinate hypertrophy, unrelated to HAART). Among the 6 discontinuations (3 in A, 3 in B), only 1 was related to adverse event (arm A: G3 depression, insomnia, weakness). VACS index, median FRS and median uRBP values did not vary from baseline to week 96. At 96-weeks all patients switched to a QD 2-drug regimen based on DRV/r + RPV maintained HIV-RNA suppression, but a single patient who showed a virological failure at week 4. CD4 counts increased overtime without significant differences between the two arms. The novel dual regimen was well tolerated with the same amount of discontinuation as the control arm. VACS index, FRS and uRBP did not differ between arms at week 96.
Collapse
Affiliation(s)
- Valentina Di Cristo
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy
| | | | - Renato Maserati
- Infectious Diseases Unit, Policlinico San Matteo Foundation, IRCCS, Pavia, Italy
| | - Marco Annovazzi Lodi
- Infectious Diseases Unit, Policlinico San Matteo Foundation, IRCCS, Pavia, Italy
| | - Giuseppe Bruno
- Infectious Diseases Unit, University of Bari, Bari, Italy
| | - Paolo Maggi
- Infectious Diseases Unit, University of Bari, Bari, Italy
| | - Anna Volpe
- Infectious Diseases Unit, University of Bari, Bari, Italy
| | - Paola Vitiello
- Infectious Diseases Unit, ASST Valle Olona, Ospedale di Circolo, Busto Arsizio, VA, Italy
| | - Clara Abeli
- Infectious Diseases Unit, ASST Valle Olona, Ospedale di Circolo, Busto Arsizio, VA, Italy
| | - Stefano Bonora
- Infectious Diseases Unit, University of Turin, Turin, Italy
| | - Micol Ferrara
- Infectious Diseases Unit, University of Turin, Turin, Italy
| | | | - Maria Letizia Oreni
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy
| | - Elisa Colella
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy
| | - Stefano Rusconi
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy
| |
Collapse
|
6
|
Fabbiani M, Ciccarelli N, Castelli V, Soria A, Borghetti A, Colella E, Moschese D, Valsecchi M, Emiliozzi A, Gori A, De Luca A, Bandera A, Di Giambenedetto S. Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. J Neurovirol 2019; 25:866-873. [PMID: 31281946 DOI: 10.1007/s13365-019-00780-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 06/10/2019] [Accepted: 06/19/2019] [Indexed: 02/07/2023]
Abstract
The contribution of HCV-related variables to cognitive impairment in HIV-HCV-coinfected patients has been poorly investigated. We selected HIV-HCV-coinfected patients undergoing cognitive examination (exploring memory, language, speed of mental processing and fine motor function) at three clinical centres. Cognitive performance was evaluated using Z-transformed scores. Logistic regression analysis was used to investigate variables associated to cognitive impairment (defined as a composite Z-score ≤ - 1). Overall, 146 HIV-HCV-coinfected patients were enrolled. Median HCV-RNA was 6.2logU/mL. HCV genotype 1a/b was the most represented (53.4%). Liver fibrosis was mild (Fib4 ≤ 1.45) in the majority of patients (44.5%). Global cognitive impairment was diagnosed in 35 (24%) subjects. Exploring each domain, a higher proportion of impairment was observed for memory (37%) followed by speed of mental processing (32.2%), fine motor functioning (24%) and language (18.5%). Among HCV-related variables, the duration of HCV infection was independently associated with global cognitive impairment (aOR 1.13 per +1 year, p = 0.016) and abnormal speed of mental processing (aOR 1.16 per +1 year, p = 0.001), while higher HCV-RNA was independently associated to fine motor functioning impairment (aOR 1.98 per +1log, p = 0.037). HCV genotype, fibrosis stage, transaminases or bilirubin levels were not related to cognitive performance. Of note, integrase inhibitor (InSTI) use was independently associated to a pathological performance in fine motor functioning (aOR 3.34, p = 0.035) and memory (aOR 3.70, p = 0.014). In conclusion, the duration of HCV infection and HCV-RNA load showed an association with cognitive impairment, suggesting a role of hepatitis-related factors in the development of cognitive disorders in HIV-HCV-coinfected patients. The association between InSTI use and altered cognitive performance should prompt investigations about potential neurotoxicity of these drugs.
Collapse
Affiliation(s)
- Massimiliano Fabbiani
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, viale Golgi 19, 27100, Pavia, Italy.
| | - Nicoletta Ciccarelli
- Department of Psychology, Catholic University, Largo Gemelli 1, 20123, Milan, Italy
| | - Valeria Castelli
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Alessandro Soria
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Alberto Borghetti
- Institute of Clinical Infectious Diseases, Fondazione Gemelli, IRCCS, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
| | - Elisa Colella
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Davide Moschese
- Institute of Clinical Infectious Diseases, Fondazione Gemelli, IRCCS, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
| | - Manuela Valsecchi
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Arianna Emiliozzi
- Institute of Clinical Infectious Diseases, Fondazione Gemelli, IRCCS, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
| | - Andrea Gori
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Andrea De Luca
- Department of Medical Biotechnologies, University of Siena, viale Bracci 16, 53100, Siena, Italy
| | - Alessandra Bandera
- Infectious Diseases Unit, S. Gerardo Hospital, via Pergolesi 33, 20900, Monza, Italy
| | - Simona Di Giambenedetto
- Institute of Clinical Infectious Diseases, Fondazione Gemelli, IRCCS, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
| |
Collapse
|
7
|
Squillace N, Bozzi G, Colella E, Gori A, Bandera A. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Des Devel Ther 2018; 12:3635-3643. [PMID: 30464395 PMCID: PMC6211373 DOI: 10.2147/dddt.s147493] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhibitor-based single-tablet regimen. This article provides a detailed description of its pharmacokinetic, efficacy, and safety profile. The pharmacokinetics of single compounds were analyzed, with a special focus on contrasts between Drv/Cobi and Drv/ritonavir (Rtv). When comparing Cobi and Rtv, multiple interactions must be taken into account: in comparison to Rtv, Cobi is a more selective CYP3A4 inhibitor and has no clinical effect on other isoenzymes inhibited by Rtv (eg, 2C8 and 2C9). Moreover, unlike Cobi, Rtv shows in vivo induction activity on some CYP isoenzymes (eg, 1A2, 2C19, 2C8, 2C9, and 2B6), glucuronyltransferases (eg, UGT1A4), and Pgp. Drv-Cobi-FTC-Taf has recently been demonstrated to be of equal efficacy to Drv-Rtv and other protease inhibitors in both experienced (EMERALD study) and naïve (AMBER study) patients. Moreover, kidney and bone safety profiles have been shown to be good, as has central nervous system tolerance. Total cholesterol:low-density-lipoprotein cholesterol and total cholesterol:high-density-lipoprotein cholesterol ratios are generally high in Drv-Cobi-FTC-Taf vs Rtv-Drv-FTC + tenofovir disoproxil fumarate. An unlikely role of Drv in influencing cardiovascular risk in HIV infection has also been reported. Kidney safety profile is influenced by Cobi, with an increase in creatinine plasma concentration of 0.05–0.1 mg/dL and a parallel glomerular filtration-rate reduction of 10 mL/min within the first 4 weeks after Cobi introduction, which remains stable during treatment. Bone and central nervous system safety profiles were found to be good in randomized clinical trials of both experienced and naïve patients. The efficacy and safety of Drv/Cobi/FTC/Taf are comparable to other drug regimens recommended for HIV treatment.
Collapse
Affiliation(s)
- Nicola Squillace
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy,
| | - Giorgio Bozzi
- Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy
| | - Elisa Colella
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy,
| | - Andrea Gori
- Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy
| | - Alessandra Bandera
- Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy,
| |
Collapse
|
8
|
Colella E, Cattaneo D, Galli L, Baldelli S, Clementi E, Galli M, Lazzarin A, Castagna A, Rusconi S, Spagnuolo V. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial. New Microbiol 2018; 41:106-111. [PMID: 29498742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 05/28/2018] [Indexed: 06/08/2023]
Abstract
The 96-week results of the Monotherapy Once a Day with Atazanavir/r (MODAt) study [NCT01511809] showed an inferior virological efficacy of atazanavir (ATV)/ritonavir monotherapy versus triple therapy, which was promptly retrieved by the reintroduction of nucleoside/nucleotide inhibitors of reverse transcriptase [N(n)RTIs]. We aimed to identify potential relationships between ATV exposure and clinical outcome in HIV-1 subjects treated with ATV/ritonavir monotherapy [ATV/r 300/100 mg] versus ATV/ritonavir triple therapy [ATV/r 300/100 mg+2NRTIs]. A chromatographic method coupled with tandem mass spectrometry was applied to analyze ATV plasma concentrations in a pharmacokinetic sub-study from the MODAt trial. Mixed linear models were used to examine the ATV plasma concentration trend during follow-up and to assess the association between ATV plasma concentrations trajectories with the study arm or the occurrence of treatment failure or drugrelated adverse events or the grading of baseline total bilirubin (<3 vs ≥3). The analyses were performed using SAS Software, release 9.4 (SAS Institute, Cary, NC, USA). Overall, ATV plasma Ctrough concentration did not vary during follow-up (slope: +0.75 ng/mL/week, 95%CI: -0.97 to 2.47, p=0.387); trajectories did not differ between study arms (p=0.527). The unadjusted model-based means (95%CI) of ATV Ctrough during follow-up were 835 (95%CI: 657-1012) ng/ml in the ATV/r monotherapy arm as compared to 911 (95%CI: 740-1082) ng/mL in the ATV/r triple therapy arm (p=0.621). Mean ATV Ctrough was similar in subjects with or without adverse events (AEs). Subjects treated with ATV/r monotherapy showed significantly higher ATV concentrations as compared to subjects without adverse events or treated with ATV/r triple therapy. ATV concentrations were associated with the grading of baseline total bilirubin and the occurrence of drug-related AEs but not with HCV infection. Our findings showed a lack of association between ATV concentrations and treatment failure both in ATV/r monotherapy and triple therapy. Conversely, these data emphasized that ATV concentrations are associated with the development of side-effects in both subjects treated with ATV/r monotherapy and subjects treated with ATV/r triple therapy.
Collapse
Affiliation(s)
- Elisa Colella
- Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy
| | - Dario Cattaneo
- Clinical Pharmacology Unit, Luigi Sacco University Hospital, Milan, Italy
| | - Laura Galli
- Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| | - Sara Baldelli
- Clinical Pharmacology Unit, Luigi Sacco University Hospital, Milan, Italy
| | - Emilio Clementi
- Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences 'Luigi Sacco' University Hospital, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Università degli Studi d
- E. Medea Scientific Institute, Bosisio Parini, Italy
| | - Massimo Galli
- Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy
| | - Adriano Lazzarin
- Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| | - Antonella Castagna
- Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| | - Stefano Rusconi
- Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy
| | - Vincenzo Spagnuolo
- Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
9
|
Peri AM, Bisi L, Cappelletti A, Colella E, Verga L, Borella C, Foresti S, Migliorino GM, Gori A, Bandera A. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report. Clin Microbiol Infect 2018; 24:785-786. [PMID: 29427802 DOI: 10.1016/j.cmi.2018.01.028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 01/21/2018] [Accepted: 01/24/2018] [Indexed: 10/18/2022]
Affiliation(s)
- A M Peri
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy.
| | - L Bisi
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - A Cappelletti
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - E Colella
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - L Verga
- Hematology Department, San Gerardo Hospital, ASST Monza (MB), Italy
| | - C Borella
- Hematology Department, San Gerardo Hospital, ASST Monza (MB), Italy
| | - S Foresti
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - G M Migliorino
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - A Gori
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| | - A Bandera
- Division of Infectious Diseases, San Gerardo Hospital, ASST Monza (MB), Italy
| |
Collapse
|
10
|
Abstract
INTRODUCTION Antiretroviral treatment of HIV infection reduces, but does not eliminate, viral replication and down modulates immune activation. The persistence of low level HIV replication in the host, nevertheless, drives a smouldering degree of immune activation that is observed throughout the natural history of disease and is the main driving force sustaining morbidity and mortality. Areas covered: Early start of antiretroviral therapy (ART) and intensive management of behavioural risk factors are possible but, at best, marginally successful ways to manage immune activation. We review alternative, possible strategies to reduce immune activation in HIV infection including timing of ART initiation and ART intensification to reduce HIV residual viremia; switch of ART to newer molecules with reduced toxicity; use of anti inflammatory/immunomodulatory agents and, finally, interventions aimed at modifying the composition of the microbiota. Expert commentary: Current therapeutic strategies to limit immune activation are only marginally successful. Because HIV eradication is currently impossible, intensive studies are needed to determine if and how immune activation can be silenced in HIV infection.
Collapse
Affiliation(s)
- Alessandra Bandera
- a Clinic of Infectious Diseases, 'San Gerardo' Hospital - ASST Monza, School of Medicine and Surgery , University Milano-Bicocca , Monza , Italy
| | - Elisa Colella
- a Clinic of Infectious Diseases, 'San Gerardo' Hospital - ASST Monza, School of Medicine and Surgery , University Milano-Bicocca , Monza , Italy
| | - Giuliano Rizzardini
- b Department of Infectious Diseases , ASST Fatebenefratelli Sacco , Milano , Italy.,c School of Clinical Medicine, Faculty of Health Science , University of the Witwatersrand , Johannesburg , South Africa
| | - Andrea Gori
- a Clinic of Infectious Diseases, 'San Gerardo' Hospital - ASST Monza, School of Medicine and Surgery , University Milano-Bicocca , Monza , Italy
| | - Mario Clerici
- d Department of Physiopathology and Transplants , University of Milano , Milano , Italy.,e Don C. Gnocchi Foundation , Istituto di Ricovero e Cura a Carattere Scientifico [IRCCS] , Milano , Italy
| |
Collapse
|
11
|
Cercato M, Servoli F, Scarinci V, Colella E, Fabi A, Bertazzi I, Sperduti I, Cognetti F, Cognetti G. Narrative Medicine: a multidisciplinary study on knowledge and application in oncology. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Antinori A, Meraviglia P, Monforte AD, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, Termini R. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. Drug Des Devel Ther 2016; 10:1589-603. [PMID: 27226708 PMCID: PMC4866750 DOI: 10.2147/dddt.s104875] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Current antiretroviral (ARV) therapy for the treatment of human immunodeficiency virus (HIV-1)-infected patients provides long-term control of viral load (VL). Darunavir (DRV) is a nonpeptidomimetic protease inhibitor approved for use with a ritonavir booster (DRV/r). This study evaluated the effectiveness of DRV/r in combination with other ARV agents in routine clinical practice in Italy. In this descriptive observational study, data on utilization of DRV/r, under the conditions described in the marketing authorization, were collected from June 2009 to December 2012. Effectiveness (VL <50 copies/mL), tolerability, and durability in four patient groups (two DRV/r-experienced, one ARV-experienced DRV/r-naïve, and one ARV-naïve) were analyzed. Secondary objectives included immunological response, safety, and persistence/discontinuation rates. In total, 875 of 883 enrolled patients were included in the analysis: of these, 662 (75.7%) completed the follow-up until the end of 2012 and 213 (24.3%) withdrew from the study earlier. Initial DRV dose was 600 mg twice daily (67.1%) or 800 mg once daily (32.9%). Only 16 patients (1.8%) withdrew from the study due to virological failure. Virological response proportions were higher in patients virologically suppressed at study entry versus patients with baseline VL ≥50 copies/mL in each ARV-experienced group, while there was no consistent difference across study groups and baseline VL strata according to baseline CD4+ cell count. CD4+ cell count increased from study entry to last study visit in all the four groups. DRV/r was well tolerated, with few discontinuations due to study-emergent nonfatal adverse events (3.0% overall, including 2.1% drug-related) or deaths (3.0% overall, all non-drug-related); 35.3% of patients reported ≥1 adverse events. These observational data show that DRV/r was effective and well tolerated in the whole patient population described here. The DRV/r-containing regimen provided viral suppression in a high percentage of patients in all groups, with low rates of discontinuation due to virological failure.
Collapse
Affiliation(s)
- Andrea Antinori
- Clinical Department, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy
| | - Paola Meraviglia
- Department of Infectious Disease, "L. Sacco" University Hospital, Milan, Italy
| | - Antonella d'Arminio Monforte
- Department of Health Sciences - University of Milan, Milan, Italy; Clinic of Infectious Diseases, "San Paolo" Hospital, Milan, Italy
| | - Antonella Castagna
- Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
| | - Cristina Mussini
- Institute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
| | - Teresa Bini
- Clinic of Infectious Diseases, "San Paolo" Hospital, Milan, Italy
| | - Nicola Gianotti
- Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
| | - Stefano Rusconi
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Cicogna, Ghirri, Italy
| | - Elisa Colella
- Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Cicogna, Ghirri, Italy
| | | | - Daniela Mancusi
- Janssen-Cilag SpA, Medical Affairs, Cologno Monzese, Milan, Italy
| | - Roberta Termini
- Janssen-Cilag SpA, Medical Affairs, Cologno Monzese, Milan, Italy
| |
Collapse
|
13
|
Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Colella E, Ridolfo AL, Galli M, Rusconi S. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. Antiviral Res 2016; 129:52-57. [PMID: 26902109 DOI: 10.1016/j.antiviral.2016.02.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 02/10/2016] [Accepted: 02/15/2016] [Indexed: 12/31/2022]
Abstract
We evaluated predictive factors involved in durability and therapeutic failure of atazanavir (ATV)-based antiretroviral regimens with or without ritonavir (r) in real life setting. This retrospective study of HIV-1-positive patients evaluated the factors related to ATV continuance and the time-dependent probability of therapeutic failure (HIV-RNA >200 copies/mL and concomitant discontinuation of ATV). We also investigated the rate of therapeutic failure and the variations in total bilirubin levels from starting unboosted ATV-based regimens. The study involved 1030 patients: 183 treatment-naïve patients (17.8%) started ATV/r (17 subsequently switched to unboosted ATV); 653 (63.4%) switched to ATV/r from previous antiretroviral regimens (121 subsequently switched to unboosted ATV); and 194 (18.8%) switched to unboosted ATV from previous ATV-free regimens. The median ATV follow-up was 28 months (interquartile range 7-56). The risk of ATV discontinuation was significantly lower in patients switched to unboosted ATV from ATV/r (HR 0.45; p < 0.0001). The discontinuation of ATV correlated with female gender (HR 1.26; p = 0.035), use of a zidovudine/didanosine/stavudine containing backbone (HR 1.8; p = 0.004), and a baseline CD4+ cell counts of <200/μL (HR 1.54; p = 0.003), the last of which was also associated with a higher risk of therapeutic failure (HR 2.42; p = 0.001). Total bilirubin levels were significantly lower in the patients switching from ATV/r to unboosted ATV. Unboosted ATV-based therapies are safe and effective options in patients whose immuno-virological conditions are stable, and allow the long-term survival of ATV-containing regimens.
Collapse
Affiliation(s)
- Andrea Giacomelli
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy.
| | - Letizia Oreni
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Marco Franzetti
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Valentina Di Cristo
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Elisa Colella
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Anna Lisa Ridolfo
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Massimo Galli
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| | - Stefano Rusconi
- Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Milan, Italy
| |
Collapse
|
14
|
Bonora S, Calcagno A, Vigano O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G, Rusconi S. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. Curr HIV Res 2015; 12:339-46. [PMID: 25106410 DOI: 10.2174/1570162x12666140807151616] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 07/07/2014] [Accepted: 07/27/2014] [Indexed: 11/22/2022]
Abstract
PURPOSE Switch to unboosted atazanavir (ATV) is an attractive option due to convenience and tolerability in HIV-positive patients. With limited available data we investigated the determinants of long-term efficacy and the consequences of virological failure of unboosted atazanavir-based regimens. METHODS Retrospective analysis in two Italian large outpatient clinics including demographic, immunovirological, resistance and pharmacokinetic data. RESULTS 249 patients receiving atazanavir (400 mg once-daily) plus 2 NRTIs were included; 163 were males (65.5%) and median age was 47 years (42-51.5). Median CD4+ T-cell count was 396/uL (261-583); 146 (58.6%) presented a viral load < 50 copies/mL. Over a median follow up of 157 weeks (106-203) 193 patients (77.5%) were still on treatment with 10 (4%) and 2 (0.8%) stopping for virological failure or toxicity, respectively. Ten patients with virological failure presented newly selected resistance associated mutations (RAMs) for NRTIs (2/10) or ATV (4/10, one I50L). Total cholesterol and triglycerides showed significant decreases at 48 [-4 mg/dL and -41 mg/dL] and 96 weeks [-14 mg/dL and -54 mg/dL] as compared to baseline. At multivariate analysis a genotypic sensitivity score ≤ 1, atazanavir RAMs > 1 and suboptimal adherence were independently associated with virological failure; in lamivudine/emtricitabine-treated patients the presence of M184V (without other NRTI RAMs) was not associated with virological failure. CONCLUSION Unboosted-atazanavir containing regimens were efficacious (with uncommon virological failures) and well-tolerated (with improvements in lipid profile over time) treatments in HIV-positive patients. Isolated M184V in lamivudine/emtricitabine recipients was not associated with higher failure rates supporting the use of functional ATV-based dual therapies as maintenance strategies.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - S Rusconi
- Ospedale Amedeo di Savoia, Clinica Universitaria I Piano, C.so Svizzera 164, 10159, Torino, Italy.
| |
Collapse
|
15
|
Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti A, Meraviglia P, Abeli C, Bonora S, D’Annunzio M, Biagio AD, Di Pietro M, Butini L, Orofino G, Colafigli M, d’Ettorre G, Francisci D, Parruti G, Soria A, Buonomini AR, Tommasi C, Mosti S, Bai F, Di Nardo Stuppino S, Morosi M, Montano M, Tau P, Merlini E, Marchetti G. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. PLoS One 2013; 8:e80157. [PMID: 24244635 PMCID: PMC3828227 DOI: 10.1371/journal.pone.0080157] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 09/26/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Immunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression. We assessed immune reconstitution profile upon intensification with maraviroc in INRs. METHODS We designed a multi-centric, randomized, parallel, open label, phase 4 superiority trial. We enrolled 97 patients on HAART with CD4+<200/µL and/or CD4+ recovery ≤ 25% and HIV-RNA<50 cp/mL. Patients were randomized 1:1 to HAART+maraviroc or continued HAART. CD4+ and CD8+ CD45+RA/RO, Ki67 expression and plasma IL-7 were quantified at W0, W12 and W48. RESULTS By W48 both groups displayed a CD4 increase without a significant inter-group difference. A statistically significant change in CD8 favored patients in arm HAART+maraviroc versus HAART at W12 (p=.009) and W48 (p=.025). The CD4>200/µL and CD4>200/µL + CD4 gain ≥ 25% end-points were not satisfied at W12 (p=.24 and p=.619) nor at W48 (p=.076 and p=.236). Patients continuing HAART displayed no major changes in parameters of T-cell homeostasis and activation. Maraviroc-receiving patients experienced a significant rise in circulating IL-7 by W48 (p=.01), and a trend in temporary reduction in activated HLA-DR+CD38+CD4+ by W12 (p=.06) that was not maintained at W48. CONCLUSIONS Maraviroc intensification in INRs did not have a significant advantage in reconstituting CD4 T-cell pool, but did substantially expand CD8. It resulted in a low rate of treatment discontinuations. TRIAL REGISTRATION ClinicalTrials.gov NCT00884858 http://clinicaltrials.gov/show/NCT00884858.
Collapse
Affiliation(s)
- Stefano Rusconi
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
| | - Paola Vitiello
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
- Divisione di Malattie Infettive, Ospedale di Circolo, Busto Arsizio (VA), Italy
| | | | - Elisa Colella
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
| | - Emanuele Focà
- Clinica di Malattie Infettive e Tropicali, Università degli Studi, Brescia, Italy
| | - Amedeo Capetti
- I Divisione di Malattie Infettive, Ospedale Luigi Sacco, Milano, Italy
| | - Paola Meraviglia
- II Divisione di Malattie Infettive, Ospedale Luigi Sacco, Milano, Italy
| | - Clara Abeli
- Divisione di Malattie Infettive, Ospedale di Circolo, Busto Arsizio (VA), Italy
| | - Stefano Bonora
- Clinica delle Malattie Infettive, Ospedale Amedeo di Savoia, Università degli Studi, Torino, Italy
| | - Marco D’Annunzio
- Clinica di Malattie Infettive, A.O.-Universitaria Policlinico, Bari, Italy
| | - Antonio Di Biagio
- Clinica delle Malattie Infettive, Ospedale San Martino, Università degli Studi, Genova, Italy
| | - Massimo Di Pietro
- Divisione di Malattie Infettive, Ospedale S. Maria Annunziata, Antella, Firenze, Italy
| | - Luca Butini
- Servizio di Immunologia Clinica e Tipizzazione. Tissutale, A.O.-Universitaria, Torrette di Ancona, Italy
| | - Giancarlo Orofino
- Divisione A di Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy
| | - Manuela Colafigli
- Istituto di clinica Delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Gabriella d’Ettorre
- U.O. Malattie Infettive, Università La Sapienza, Policlinico Umberto I, Roma, Italy
| | - Daniela Francisci
- Clinica delle Malattie Infettive, Policlinico Monteluce, Perugia, Italy
| | - Giustino Parruti
- Divisione Clinicizzata di Malattie Infettive, Ospedale Santo Spirito, Pescara, Italy
| | - Alessandro Soria
- Divisione Clinicizzata di Malattie Infettive, Ospedale san Gerardo, Monza, Italy
| | | | - Chiara Tommasi
- III Divisione di Malattie Infettive I.N.M.I “Lazzaro Spallanzani”, Roma, Italy
| | - Silvia Mosti
- IV Divisione di Malattie Infettive I.N,M.I “Lazzaro Spallanzani”, Roma, Italy
| | - Francesca Bai
- Clinica delle Malattie Infettive, Dipartimento di Scienze della Salute, Polo Universitario San Paolo, Università degli Studi, Milano, Italy
| | - Silvia Di Nardo Stuppino
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
| | - Manuela Morosi
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
| | - Marco Montano
- Clinica delle Malattie Infettive, Policlinico "Tor Vergata", Roma, Italy
| | - Pamela Tau
- Divisione Clinicizzata di Malattie Infettive, DIBIC “Luigi Sacco”, Università degli Studi, Milano, Italy
| | - Esther Merlini
- Clinica delle Malattie Infettive, Dipartimento di Scienze della Salute, Polo Universitario San Paolo, Università degli Studi, Milano, Italy
| | - Giulia Marchetti
- Clinica delle Malattie Infettive, Dipartimento di Scienze della Salute, Polo Universitario San Paolo, Università degli Studi, Milano, Italy
| |
Collapse
|
16
|
Milazzo L, Cattaneo D, Cheli S, Ferraris L, Colella E, Clementi E, Gervasoni C. ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor? Eur J Clin Pharmacol 2012; 69:743-5. [PMID: 22990328 DOI: 10.1007/s00228-012-1397-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Accepted: 08/29/2012] [Indexed: 12/01/2022]
|
17
|
Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti AF, Meraviglia P, Abeli C, Bonora S, D'Annunzio M, Di Biagio A, Di Pietro A, Butini L, Orofino G, Farina S, d'Ettorre G, Francisci D, Soria A, Buonomini AR, Tommasi C, Trotta MP, Capasso M, Merlini E, Marchetti GC. Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART. J Int AIDS Soc 2010. [PMCID: PMC3112859 DOI: 10.1186/1758-2652-13-s4-o44] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
18
|
Bonora S, Calcagno A, Viganò O, Bigliano P, Rusconi S, Trentini L, Tettoni MC, Orofino G, Salassa B, Bramato C, D'Avolio A, Siccardi M, Colella E, Galli M, Di Perri G. Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting. J Int AIDS Soc 2010. [PMCID: PMC3113051 DOI: 10.1186/1758-2652-13-s4-p48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
19
|
Verdina A, Tonachella R, Colella E, Falasca G, Galati R. Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment. J Exp Clin Cancer Res 2002; 21:337-40. [PMID: 12385574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.
Collapse
Affiliation(s)
- A Verdina
- Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | |
Collapse
|
20
|
Colella E, Merlano M, Blengio F, Angelini F, Ausili Cefaro GP, Scasso F, Lo Russo V, Cirulli S, Giannarelli D, Cognetti F. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. Eur J Cancer 1994; 30A:928-30. [PMID: 7946585 DOI: 10.1016/0959-8049(94)90116-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Between March 1990 and March 1992, 89 patients with recurrent and/or metastatic squamous cell cancer of the head and neck were randomised to receive either intravenous methotrexate (MTX) at a weekly dose of 40 mg/m2 plus lonidamine (LND) given orally at a starting dose of 75 mg three times daily for 3 days and then at a dose of 150 mg three times daily (arm MTX + LND) or methotrexate alone (arm MTX) at the same doses as arm MTX + LND. Complete remissions were observed in 10.5% of the patients in arm MTX + LND, and partial remissions in another 15.8%, yielding a 26.3% response rate. In arm MTX, only partial remissions were observed, yielding an overall response rate of 18.2%. Haematological toxicity was mild in both groups. Mild testicular pain (21%) and myalgias (31%) occurred only in patients treated with LND.
Collapse
Affiliation(s)
- E Colella
- Regina Elena National Cancer Institute, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Speziale F, Taurino M, Colella E, Rizzo L, Fiorani P. [Clinical study of picotamide in patients with vascular diseases]. Recenti Prog Med 1989; 80:271-5. [PMID: 2762664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The authors report on a group of 44 patients operated on for vascular disease, treated with antiplatelet therapy (picotamide). These patients were followed up for a period of 12 months with clinical and instrumental controls (Doppler ultrasound) in order to evaluate the evolution of atherosclerotic disease.
Collapse
|
22
|
Ippoliti A, Podda I, Colella E, Giannoni MF. [Clinico-therapeutic considerations on arterial embolism of the legs]. G Chir 1988; 9:438-42. [PMID: 3155204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
23
|
Taurino M, Nicolini G, Colella E, De Santis F, Rizzo L, Massucci M, Sbarigia E. [Importance of the associated carotid and coronary lesions in interventions of revascularization of the aorto-iliac area]. G Chir 1988; 9:446-8. [PMID: 3155206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|